Sarepta price target raised to $35 from $22 at RW Baird Baird raised its price target on Sarepta following its update on pulmonary data that provides incremental evidence of efficacy of its 6MWT results from last month. The firm expects the next catalyst to be clarity on its pivotal trial design. Shares are Outperform rated.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sarepta said to cancel appearance at Needham conference Sarepta cancelled its appearance at Needham's conference tomorrow due to "other obligations," a re-tweet by The Street's Adam Feuerstein says, citing a confirmation from the company. Shares of Sarepta moved up 23c to $23.37 following circulation of the tweet.